CN107383062B - 头孢布烯母核7-ance的制备方法 - Google Patents
头孢布烯母核7-ance的制备方法 Download PDFInfo
- Publication number
- CN107383062B CN107383062B CN201710774269.9A CN201710774269A CN107383062B CN 107383062 B CN107383062 B CN 107383062B CN 201710774269 A CN201710774269 A CN 201710774269A CN 107383062 B CN107383062 B CN 107383062B
- Authority
- CN
- China
- Prior art keywords
- ceftibuten
- preparation
- ance
- added
- parent nucleus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960004086 ceftibuten Drugs 0.000 title claims abstract description 29
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 84
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims abstract description 39
- 238000006243 chemical reaction Methods 0.000 claims abstract description 23
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims abstract description 19
- LIBASNWCFRYHQB-UHFFFAOYSA-N (2,3-dichlorophenyl)-diphenylphosphane Chemical compound ClC1=CC=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1Cl LIBASNWCFRYHQB-UHFFFAOYSA-N 0.000 claims abstract description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000010792 warming Methods 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims abstract description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims abstract description 7
- UVJAWYKDJJXIMZ-BAFYGKSASA-N (6r)-3-hydroxy-5-thia-1-azabicyclo[4.2.0]octan-8-one Chemical compound C1C(O)CS[C@@H]2CC(=O)N21 UVJAWYKDJJXIMZ-BAFYGKSASA-N 0.000 claims abstract description 5
- 229960000583 acetic acid Drugs 0.000 claims abstract description 5
- 239000012362 glacial acetic acid Substances 0.000 claims abstract description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 5
- 229910000085 borane Inorganic materials 0.000 claims abstract description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims abstract description 4
- -1 reduzate I Chemical compound 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 17
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000007787 solid Substances 0.000 claims description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 235000019441 ethanol Nutrition 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000012074 organic phase Substances 0.000 claims description 4
- 239000012266 salt solution Substances 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 238000013517 stratification Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 2
- 229910052796 boron Inorganic materials 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 239000011260 aqueous acid Substances 0.000 claims 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical class ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 16
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 6
- 238000010511 deprotection reaction Methods 0.000 abstract description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 239000002274 desiccant Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- RJFPBECTFIUTHB-INEUFUBQSA-N (6r,7r)-7-azaniumyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound S1CC=C(C(O)=O)N2C(=O)[C@@H](N)[C@H]21 RJFPBECTFIUTHB-INEUFUBQSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000010907 mechanical stirring Methods 0.000 description 2
- 229910000474 mercury oxide Inorganic materials 0.000 description 2
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ITLHXEGAYQFOHJ-UHFFFAOYSA-N [diazo(phenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(=[N+]=[N-])C1=CC=CC=C1 ITLHXEGAYQFOHJ-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001991 ceftizoxime Drugs 0.000 description 1
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
- YGBFLZPYDUKSPT-MRVPVSSYSA-N cephalosporanic acid Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)C[C@H]21 YGBFLZPYDUKSPT-MRVPVSSYSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical group O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940124588 oral cephalosporin Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/18—7-Aminocephalosporanic or substituted 7-aminocephalosporanic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/02—Preparation
- C07D501/04—Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/02—Preparation
- C07D501/12—Separation; Purification
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cephalosporin Compounds (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710774269.9A CN107383062B (zh) | 2017-08-31 | 2017-08-31 | 头孢布烯母核7-ance的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710774269.9A CN107383062B (zh) | 2017-08-31 | 2017-08-31 | 头孢布烯母核7-ance的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107383062A CN107383062A (zh) | 2017-11-24 |
CN107383062B true CN107383062B (zh) | 2019-11-05 |
Family
ID=60349129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710774269.9A Active CN107383062B (zh) | 2017-08-31 | 2017-08-31 | 头孢布烯母核7-ance的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107383062B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110878101A (zh) * | 2019-12-11 | 2020-03-13 | 华中药业股份有限公司 | 一种制备头孢沙定母核7-amoca的新方法 |
CN112759602B (zh) * | 2020-10-14 | 2022-07-01 | 湖北凌晟药业有限公司 | 一种制备头孢布烯母核7-ance的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4389524A (en) * | 1972-06-29 | 1983-06-21 | Ciba-Geigy Corporation | Cepham compounds |
US4647658A (en) * | 1984-06-08 | 1987-03-03 | Shionogi & Co., Ltd. | Process for preparing aminohydroxycephamcarboxylates |
CN101357927A (zh) * | 2008-07-29 | 2009-02-04 | 浙江普洛得邦制药有限公司 | 7-氨基-3-无-3-头孢-4-羧酸的制备方法 |
CN102617600A (zh) * | 2012-02-23 | 2012-08-01 | 苏州中联化学制药有限公司 | 7-氨基-3-无-3-头孢环-4-羧酸的合成方法 |
CN103374018A (zh) * | 2012-04-26 | 2013-10-30 | 黄山市歙县宏辉化工有限公司 | 一种制备头孢布烯母核7-nacabh的新方法 |
-
2017
- 2017-08-31 CN CN201710774269.9A patent/CN107383062B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4389524A (en) * | 1972-06-29 | 1983-06-21 | Ciba-Geigy Corporation | Cepham compounds |
US4647658A (en) * | 1984-06-08 | 1987-03-03 | Shionogi & Co., Ltd. | Process for preparing aminohydroxycephamcarboxylates |
CN101357927A (zh) * | 2008-07-29 | 2009-02-04 | 浙江普洛得邦制药有限公司 | 7-氨基-3-无-3-头孢-4-羧酸的制备方法 |
CN102617600A (zh) * | 2012-02-23 | 2012-08-01 | 苏州中联化学制药有限公司 | 7-氨基-3-无-3-头孢环-4-羧酸的合成方法 |
CN103374018A (zh) * | 2012-04-26 | 2013-10-30 | 黄山市歙县宏辉化工有限公司 | 一种制备头孢布烯母核7-nacabh的新方法 |
Non-Patent Citations (1)
Title |
---|
头孢克罗的合成方法研究;王辉,等;《河北科技大学学报》;20080630;第29卷(第2期);第146-148页,尤其参见第147页图1,第1.2-1.3节 * |
Also Published As
Publication number | Publication date |
---|---|
CN107383062A (zh) | 2017-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1984898A (zh) | 生产薁衍生物的方法和合成该薁衍生物的中间体 | |
CN107383062B (zh) | 头孢布烯母核7-ance的制备方法 | |
JP2020525574A (ja) | スガマデックスの製造方法 | |
CN113801010A (zh) | 一种5-溴-2-氯苯甲酸的制备方法 | |
CN102424673B (zh) | 孟鲁司特钠中间体及孟鲁司特钠的合成方法 | |
CN112812107B (zh) | 一种sglt-2抑制剂及中间体的制备方法 | |
JP5646706B2 (ja) | C−グリコシド誘導体の製造方法 | |
CN102633819A (zh) | 一种头孢西丁的制备方法 | |
CN112759602B (zh) | 一种制备头孢布烯母核7-ance的方法 | |
CN103936638B (zh) | 氟苯尼考的合成方法 | |
CN110878101A (zh) | 一种制备头孢沙定母核7-amoca的新方法 | |
CN116444597A (zh) | 一种制备去氧胆酸中间体和去氧胆酸的方法 | |
CN112125942B (zh) | 醋酸阿比特龙及其中间体的合成方法 | |
CN108101911A (zh) | 一种西格列汀中间体的合成工艺 | |
CN111454315B (zh) | 一种雄甾-16-烯-3β-醇的合成方法 | |
CN104961675B (zh) | 一种艾沙康唑中间体的制备方法 | |
CN108148061B (zh) | 恩替卡韦的工业化制备方法 | |
CN113372375A (zh) | 一种坦西莫司中间体的制备方法 | |
CN111217709A (zh) | 一种(1-氟环丙基)甲胺盐酸盐的制备方法 | |
CN105753827A (zh) | 制备化合物的方法 | |
CN111253392A (zh) | 一种制备阿哌沙班的方法 | |
JPS631952B2 (zh) | ||
CN111072500A (zh) | 一种盐酸氨溴索的制备方法 | |
CN102558198A (zh) | 一种合成7-anca的新工艺 | |
CN111233922A (zh) | 新化合物及其用于合成磷霉素杂质b的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210812 Address after: 441141 Xiangcheng Economic Development Zone, Xiangcheng District, Xiangyang City, Hubei Province Patentee after: HUBEI LINGSHENG PHARMACEUTICAL Co.,Ltd. Address before: 441141 No. 1, No. 10 road, Xiangcheng Economic Development Zone, Xiangyang City, Hubei Province Patentee before: HUBEI LINGSHENG PHARMACEUTICAL Co.,Ltd. Patentee before: WUHAN INSTITUTE OF TECHNOLOGY |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 441048 Xiangcheng Economic Development Zone, Xiangcheng District, Xiangyang City, Hubei Province Patentee after: Hubei Lingsheng Pharmaceutical Co.,Ltd. Address before: 441141 Xiangcheng Economic Development Zone, Xiangcheng District, Xiangyang City, Hubei Province Patentee before: HUBEI LINGSHENG PHARMACEUTICAL CO.,LTD. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation method of cephalosporin mother nucleus 7-ANCE Granted publication date: 20191105 Pledgee: Agricultural Bank of China Limited Xiangyang High tech Zone Branch Pledgor: Hubei Lingsheng Pharmaceutical Co.,Ltd. Registration number: Y2024980002009 |